| 摘要 |
Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain R<1 >and a second peptide chain R<2>, wherein R<1 >and R<2 >may be the same or different, and are linked through a linking moiety. R<1 >is approximately 10 to 40 amino acid residues in length and comprises the sequence X3X4X5GPX6TX7X8X9 (SEQ ID NO: 1) wherein X3 is C or Hoc, X4 is R, H, L or W, X5 is M, F, I or nor-leucine (J), X6 is any one of the 20 genetically coded L-amino acids or J, X7 is W, 1-naphthylalanine (B) or 2-naphthylalanine (U), X8 is D, E, 1, L or V, and X9 is C or Hoc. Similarly, R<2 >comprises the sequence X'3X'4X'5GPX'6TX'7X'8X'9 (SEQ ID NO: 2) wherein X'3 is C or Hoc, X'4 is R, H, L or W, X'5 is M, F, I or J, X'6 is any one of the 20 genetically coded L-amino acids or J, X'7 is W, B or U, X8' is D, E, I, L or V, and X'9 is C or Hoc. Methods for synthesizing the compounds are provided as well, as are pharmaceutical compositions and methods of use.
|
